InvestSMART

Factor Therapeutics Limited (ASX: FTT) - Announcements

- Current share price for FTT : $0.005

ASX company news and announcements for Factor Therapeutics Limited (FTT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Factor Therapeutics Limited (FTT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Factor Therapeutics Limited (FTT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Factor Therapeutics Limited (FTT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Factor Therapeutics Appoints Transaction Advisor 16 Oct 2018 8:30AM $0.067 $0.005 fallen by 92.54%
- Last patient completes treatment in VLU Ph 2 Clinical Trial 4 Oct 2018 8:41AM $0.080 $0.005 fallen by 93.75%
- Shareholder Update Q3 2018 2 Oct 2018 8:26AM $0.072 $0.005 fallen by 93.06%
- Phase 2 Trial for Venous Leg Ulcers Nears Completion 6 Sep 2018 8:35AM $0.050 $0.005 fallen by 90%
- Half Yearly Report and Accounts 23 Aug 2018 12:32PM $0.052 $0.005 fallen by 90.38%
- CEO presentation to Broker Meets Biotech - Perth 16 Aug 2018 3:41PM $0.055 $0.005 fallen by 90.91%
- Appendix 4C - June 2018 quarter 27 Jul 2018 3:42PM $0.055 $0.005 fallen by 90.91%
- CEO Presentation to Bioshares Conference 27 Jul 2018 8:21AM $0.055 $0.005 fallen by 90.91%
- Recruitment complete in VF00102 Phase 2 clinical trial 16 Jul 2018 8:24AM $0.060 $0.005 fallen by 91.67%
- Screening to close as clinical trial nears completion 26 Jun 2018 8:21AM $0.044 $0.005 fallen by 88.64%
- Clinical Trial Update 14 Jun 2018 12:24PM $0.046 $0.005 fallen by 89.13%
- AGM Results of Meeting 24 May 2018 5:43PM $0.040 $0.005 fallen by 87.50%
- Chairman and CEO Address to Annual General Meeting 24 May 2018 2:05PM $0.044 $0.005 fallen by 88.64%
- Receipt of $1.23M R&D tax incentive 15 May 2018 11:08AM $0.040 $0.005 fallen by 87.50%
- Clinical trial update - recruitment enters final phase 14 May 2018 8:27AM $0.040 $0.005 fallen by 87.50%
- Ceasing to be a substantial holder 4 May 2018 4:52PM $0.039 $0.005 fallen by 87.18%
- Appendix 4C - March 2018 Quarter 26 Apr 2018 11:13AM $0.041 $0.005 fallen by 87.80%
- Appendix 3Y - C Behrenbruch 24 Apr 2018 11:13AM $0.041 $0.005 fallen by 87.80%
- Appendix 3Y - C Hirst 24 Apr 2018 11:13AM $0.041 $0.005 fallen by 87.80%
- Appendix 3Y - J Michailidis 24 Apr 2018 11:12AM $0.041 $0.005 fallen by 87.80%
- Change in substantial holding 23 Apr 2018 5:01PM $0.042 $0.005 fallen by 88.10%
- Notice of Annual General Meeting/Proxy Form 20 Apr 2018 12:20PM $0.042 $0.005 fallen by 88.10%
- Appendix 3B - allotment of Rights Issue shares complete 19 Apr 2018 8:30AM $0.045 $0.005 fallen by 88.89%
- Completion of entitlement offer 13 Apr 2018 11:00AM $0.040 $0.005 fallen by 87.50%
- Clinical Trial update - March quarter 10 Apr 2018 8:20AM $0.042 $0.005 fallen by 88.10%

126 - 150 of 260 results

Page 6 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.